Porustobart (HBM4003)
Melanoma, Colorectal Cancer, Hepatocellular Carcinoma, Neuroendocrine Neoplasm
Phase 2/3Active (Greater China)
Key Facts
Indication
Melanoma, Colorectal Cancer, Hepatocellular Carcinoma, Neuroendocrine Neoplasm
Phase
Phase 2/3
Status
Active (Greater China)
Company
About Harbour BioMed
Harbour BioMed is a publicly traded biotech (HKEX: 02142) with a mission to deliver breakthrough medicines through its innovative antibody technology platforms. The company has successfully transitioned from a technology licensor to a clinical-stage entity with a maturing pipeline, evidenced by multiple out-licensing deals and strategic collaborations with major pharmaceutical companies. Its 'global for global' strategy leverages R&D centers in the US, Europe, and China to build a diversified portfolio of novel therapeutics.
View full company profile